RGTI
Rigetti Computing
-- 17.0800 TSLA
Tesla
-- 431.660 NVDA
NVIDIA
-- 137.010 LAES
SEALSQ Corp
-- 9.080 PLTR
Palantir
-- 79.080 
There’s a chance some nice big sales come from this?
$Daxor (DXR.US)$ DAXOR'S INNOVATIVE BVA-100 BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24
GlobeNewswire·
Elite Cardiovascular Leaders Unite: Driving Innovation Through Shared Excellence
Oak Ridge, TN, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall'24 Conference being held at the Gaylord Rockies Resort & Convention Center in Aurora, CO, October 17-19, 2024. The CV Transforum is the leading conference for cardiovascular organizational performance solutions, uniting cardiovascular thought-leaders from across the country to transform cardiovascular care together with leading industry innovators.
"We look forward to engaging with industry leaders at this pivotal gathering, connecting with top cardiovascular innovators to demonstrate how our blood volume analysis technology directly tackles key challenges: hospital readmissions, mortality rates, and resource optimization. MedAxiom's reputation for introducing outcome-improving, cost-reducing solutions makes this the ideal platform to highlight our technology," said Michael Feldschuh, Daxor's CEO and President.
BVA guided care has been shown in peer-reviewed studies to significantly improve multiple measures of patient outcomes, including reduction in 30-day mortality by 82%, 1-year mortality by 86%, 30-day readmissions by 56%, and also results in a 57% reduction in length of stay when performed upon admission (P<0.001). BVA technology provides clinicians with 98% accurate, actionable data to optimize treatment plans and individualize care, improving outcomes while reducing duration and cost.
GlobeNewswire·
Elite Cardiovascular Leaders Unite: Driving Innovation Through Shared Excellence
Oak Ridge, TN, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall'24 Conference being held at the Gaylord Rockies Resort & Convention Center in Aurora, CO, October 17-19, 2024. The CV Transforum is the leading conference for cardiovascular organizational performance solutions, uniting cardiovascular thought-leaders from across the country to transform cardiovascular care together with leading industry innovators.
"We look forward to engaging with industry leaders at this pivotal gathering, connecting with top cardiovascular innovators to demonstrate how our blood volume analysis technology directly tackles key challenges: hospital readmissions, mortality rates, and resource optimization. MedAxiom's reputation for introducing outcome-improving, cost-reducing solutions makes this the ideal platform to highlight our technology," said Michael Feldschuh, Daxor's CEO and President.
BVA guided care has been shown in peer-reviewed studies to significantly improve multiple measures of patient outcomes, including reduction in 30-day mortality by 82%, 1-year mortality by 86%, 30-day readmissions by 56%, and also results in a 57% reduction in length of stay when performed upon admission (P<0.001). BVA technology provides clinicians with 98% accurate, actionable data to optimize treatment plans and individualize care, improving outcomes while reducing duration and cost.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment